Healthcare >> Analyst Interviews >> April 1, 2014

Targeted Genetic and Cell Therapies Stand Out in Biotechnology

Nierengarten, David
David Nierengarten, Ph.D., is Managing Director and Head of Healthcare Equity Research at Wedbush Securities. He is a senior biotechnology equity analyst with Wedbush Securities, mainly covering development-stage therapeutic companies. He began his career on the financial side of biotechnology at a venture capital firm that focused on early-stage therapeutic and medical device companies. Additionally, prior to joining Wedbush, Dr. Nierengarten gained experience on the other side of that equation, working in a clinical-stage, venture-backed biotechnology company, in business development and clinical trial operations. He received his bachelor’s degree in biochemistry from the University of Wisconsin-Madison and his Ph.D. in molecular and cell biology from the University of California-Berkeley.   Profile
TWST: Start it off by telling us about your coverage universe.

Dr. Nierengarten: I cover mainly oncology and rare disease companies, as well as hematology/oncology companies. My group